Alan W. Partin

Citirano

	Sve	Od 2020.
Citati	87322	15680
H-indeks	135	61
i10-indeks	553	258

4500

2250

1125

3375

199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025251 335 380 600 667 985 1177 1563 1699 1775 2500 2623 2784 2657 3048 3271 3464 3806 3797 4208 4146 4432 4150 4341 4047 3690 3295 3595 3573 3121 2539 2484 352

Javni pristup

Prikaži sve

128 članaka

17 članaka

dostupno

nije dostupno

Na temelju uvjeta financiranja

Suautori

Jonathan EpsteinJohns Hopkins Medical InstitutionsPotvrđena adresa e-pošte na jhmi.edu
Misop HanProfessor of UrologyPotvrđena adresa e-pošte na jhmi.edu
Lori SokollJohns Hopkins UniversityPotvrđena adresa e-pošte na jhmi.edu
Mario EisenbergerProfessor of Oncology,Johns Hopkins UniversityPotvrđena adresa e-pošte na jhmi.edu
Stephen J FreedlandCedars-Sinai Medical CenterPotvrđena adresa e-pošte na cshs.org
Danil MakarovAssociate Professor of Urology and Health Policy, NYU School of MedicinePotvrđena adresa e-pošte na nyumc.org
Edward M Schaeffer, MD PhDNorthwestern UniversityPotvrđena adresa e-pošte na northwestern.edu
William CatalonaProfessor of urology, northwestern universityPotvrđena adresa e-pošte na nm.org
William B. IsaacsProfessor of Urology and Oncology, Brady Urological Inst, Johns Hopkins Univ, School of MedicinePotvrđena adresa e-pošte na jhmi.edu
Martin G SandaProfessor and Chairman of Urology, Emory University School of MedicinePotvrđena adresa e-pošte na emory.edu
Phillip PierorazioProfessor of Urology; Chief of Urology, Penn Presbyterian Medical Center, University of PennsylvaniaPotvrđena adresa e-pošte na pennmedicine.upenn.edu
Jeffrey TosoianAssistant Professor, Urologic Oncology, Vanderbilt University Medical CenterPotvrđena adresa e-pošte na vumc.org
George J Netto MDUniversity of Pennsylvania Perleman School of Medicine.Potvrđena adresa e-pošte na pennmedicine.upenn.edu
Kattan, Michael WChairman Department of Quantitative Health Sciences, Cleveland ClinicPotvrđena adresa e-pošte na ccf.org
Eric A. KleinChairman Emeritus, Glickman Urological and Kidney Institute, Cleveland ClinicPotvrđena adresa e-pošte na ccf.org
Angelo M. De Marzo M.D., Ph.D.Professor of Pathology, Urology and Oncology, The Johns Hopkins University School of MedicinePotvrđena adresa e-pošte na jhmi.edu
William G. NelsonProfessor of Oncology, Johns Hopkins University School of MedicinePotvrđena adresa e-pošte na jhmi.edu
Samir TanejaProfessor of Urology and RadiologyPotvrđena adresa e-pošte na nyumc.org
Elizabeth A. PlatzProfessor, Department of Epidemiology, Johns Hopkins Bloomberg School of PublicPotvrđena adresa e-pošte na jhu.edu
Kenneth PientaProfessor of Urology, Oncology, Pharmacology and Molecular Sciences, Johns Hopkins UniversityPotvrđena adresa e-pošte na jhmi.edu

Prati

Alan W. Partin

Johns Hopkins

Potvrđena adresa e-pošte na jhmi.edu

Urology Oncology


Naslov Poredaj po navodima Poredaj po godini Poredaj po naslovu	Citirano Citirano	Godina
Mortality results from a randomized prostate-cancer screening trial GL Andriole, ED Crawford, RL Grubb III, SS Buys, D Chia, TR Church, ... New England journal of medicine 360 (13), 1310-1319, 2009	4095	2009
Natural history of progression after PSA elevation following radical prostatectomy CR Pound, AW Partin, MA Eisenberger, DW Chan, JD Pearson, PC Walsh Jama 281 (17), 1591-1597, 1999	3837	1999
Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update AW Partin, MW Kattan, ENP Subong, PC Walsh, KJ Wojno, JE Oesterling, ... Jama 277 (18), 1445-1451, 1997	2568	1997
Campbell-walsh urology E-book: 4-volume set AJ Wein, LR Kavoussi, AW Partin, CA Peters Elsevier Health Sciences, 2015	2471	2015
Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial WJ Catalona, AW Partin, KM Slawin, MK Brawer, RC Flanigan, A Patel, ... Jama 279 (19), 1542-1547, 1998	1789	1998
Risk of prostate cancer–specific mortality following biochemical recurrence after radical prostatectomy SJ Freedland, EB Humphreys, LA Mangold, M Eisenberger, FJ Dorey, ... Jama 294 (4), 433-439, 2005	1732	2005
The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer AW Partin, J Yoo, HB Carter, JD Pearson, DW Chan, JI Epstein, PC Walsh The Journal of urology 150 (1), 110-114, 1993	1680	1993
Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium AW Partin, LA Mangold, DM Lamm, PC Walsh, JI Epstein, JD Pearson Urology 58 (6), 843-848, 2001	1485	2001
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience M Han, AW Partin, CR Pound, JI Epstein, PC Walsh Urologic Clinics of North America 28 (3), 555-565, 2001	1345	2001
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer R Hu, TA Dunn, S Wei, S Isharwal, RW Veltri, E Humphreys, M Han, ... Cancer research 69 (1), 16-22, 2009	1337	2009
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24 J Gudmundsson, P Sulem, A Manolescu, LT Amundadottir, ... Nature genetics 39 (5), 631-637, 2007	1018	2007
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer M Han, AW Partin, M Zahurak, S Piantadosi, JI Epstein, PC Walsh The Journal of urology 169 (2), 517-523, 2003	1005	2003
Prostate specific antigen: a decade of discovery-what we have learned and where we are going TJ Polascik, JE Oesterling, AW Partin The Journal of urology 162 (2), 293-306, 1999	962	1999
Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years PC Walsh, AW Partin, JI Epstein The Journal of urology 152 (5), 1831-1836, 1994	934	1994
Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia AW Partin, HB Carter, DW Chan, JI Epstein, JE Oesterling, RC Rock, ... The Journal of urology 143 (4), 747-752, 1990	882	1990
Prognostic G leason grade grouping: data based on the modified G leason scoring system PM Pierorazio, PC Walsh, AW Partin, JI Epstein BJU international 111 (5), 753-760, 2013	876	2013
Germline Mutations in HOXB13 and Prostate-Cancer Risk CM Ewing, AM Ray, EM Lange, KA Zuhlke, CM Robbins, WD Tembe, ... New England Journal of Medicine 366 (2), 141-149, 2012	847	2012
Prostate cancer–specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy BJ Trock, M Han, SJ Freedland, EB Humphreys, TL DeWeese, AW Partin, ... Jama 299 (23), 2760-2769, 2008	802	2008
Prostate-specific antigen after anatomic radical retropubic prostatectomy: patterns of recurrence and cancer control CR Pound, AW Partin, JI Epstein, PC Walsh Urologic Clinics of North America 24 (2), 395-406, 1997	795	1997
Predicting 15-year prostate cancer specific mortality after radical prostatectomy SE Eggener, PT Scardino, PC Walsh, M Han, AW Partin, BJ Trock, Z Feng, ... The Journal of urology 185 (3), 869-875, 2011	780	2011

Sustav trenutno ne može provesti ovu radnju. Pokušajte ponovo kasnije.

Članci 1–20

Godišnji broj citata

Dvostruki navodi

Spojeni navodi

Dodavanje suautoraSuautori

Prati

Citirano

Suautori